| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | salermide | CTRPv2 | pan-cancer | AAC | -0.004 | 0.9 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | -0.0049 | 0.9 |
| mRNA | MK 1775 | CTRPv2 | pan-cancer | AAC | 0.0028 | 0.9 |
| mRNA | decitabine:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0024 | 0.9 |
| mRNA | BHG712 | GDSC1000 | pan-cancer | AAC | -0.0025 | 0.9 |
| mRNA | TG-101348 | CTRPv2 | pan-cancer | AAC | 0.0026 | 0.9 |
| mRNA | BMS-536924 | GDSC1000 | pan-cancer | AAC | -0.0025 | 0.9 |
| mRNA | PD-0325901 | gCSI | pan-cancer | AAC | -0.0041 | 0.9 |
| mRNA | MK-2206 | GDSC1000 | pan-cancer | AAC | 0.0027 | 0.9 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.0027 | 0.9 |